Agilent Technologies price to free cash flow A
Market value divided by free cash flow over the last twelve months, since 2010.
- Today, Oct 23, 2026
- 38.5×
- 10-year median
- 30.4×
- Against its 10-year history
- 83rd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 20.6× to 49.6×
- Peer median
- 30.7×
Agilent Technologies' price to free cash flow is 38.5× as of Oct 23, 2026.
That is above its ten-year median of 30.4×, higher than on 83% of days in the last ten years.
Over that time it ranged from 20.6× in Oct 2016 to 49.6× in Dec 2020.
The median for 10 diagnostics and research stocks of a similar size is 30.7×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 38.5× | 29.9× | 41.3× |
| 2025 | 34.1× | 22.3× | 40.0× |
| 2024 | 28.2× | 23.2× | 30.0× |
| 2023 | 27.6× | 21.2× | 45.5× |
| 2022 | 43.4× | 28.0× | 45.5× |
| 2021 | 37.2× | 32.4× | 49.0× |
| 2020 | 45.3× | 27.6× | 49.6× |
| 2019 | 30.6× | 22.9× | 30.6× |
| 2018 | 23.1× | 22.2× | 33.9× |
| 2017 | 30.3× | 23.4× | 33.6× |
| 2016 | 22.4× | 20.6× | 33.3× |
| 2015 | 35.3× | 25.0× | 69.6× |
| 2014 | 27.4× | 13.7× | 27.4× |
| 2013 | 14.2× | 9.2× | 14.2× |
| 2012 | 9.6× | 8.3× | 11.1× |
| 2011 | 8.1× | 8.1× | 19.5× |
| 2010 | 17.3× | 17.0× | 22.8× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Agilent Technologies' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| AAgilent Technologies | 38.5× |
| IQVIQVIA | 21.1× |
| WATWaters | 112× |
| IDXXIDEXX Laboratories | 35.2× |
| ILMNIllumina | 43.7× |
| MTDMettler-Toledo International | 38.7× |
| DGXQuest Diagnostics | 19.8× |
| LHLabcorp | 23.1× |
| MEDPMedpace | 26.4× |
| RVTYRevvity | 31.7× |
| DHRDanaher | 29.6× |
| Peer median | 30.7× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Agilent Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.